Jasper Hellweg
Stock Analyst at Argus Research
(2.14)
# 2,907
Out of 5,050 analysts
90
Total ratings
48.61%
Success rate
3.98%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BAX Baxter International | Downgrades: Hold | n/a | $18.00 | - | 3 | Oct 31, 2025 | |
| ZTS Zoetis | Reiterates: Buy | $190 | $120.24 | +58.02% | 7 | Sep 9, 2025 | |
| BIIB Biogen | Downgrades: Hold | n/a | $155.51 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $448.91 | -10.90% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $121.90 | +23.05% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $49.66 | +20.82% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $657.53 | +77.94% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $409.47 | +34.32% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $84.58 | +0.50% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $45.68 | +173.64% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $140 | $24.54 | +470.50% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $219.16 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $23.97 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $210.46 | +37.79% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $68.26 | +46.50% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $252.72 | +16.73% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $10.16 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $179.50 | -24.79% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $14.44 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $207.59 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $28.71 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $476.61 | -67.48% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $63.70 | +41.29% | 1 | Sep 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $104 | $92.31 | +12.66% | 1 | Sep 18, 2017 |
Baxter International
Oct 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $18.00
Upside: -
Zoetis
Sep 9, 2025
Reiterates: Buy
Price Target: $190
Current: $120.24
Upside: +58.02%
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $155.51
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $448.91
Upside: -10.90%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $121.90
Upside: +23.05%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $49.66
Upside: +20.82%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $657.53
Upside: +77.94%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $409.47
Upside: +34.32%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $84.58
Upside: +0.50%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $45.68
Upside: +173.64%
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $24.54
Upside: +470.50%
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $219.16
Upside: -
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $23.97
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $210.46
Upside: +37.79%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $68.26
Upside: +46.50%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $252.72
Upside: +16.73%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.16
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $179.50
Upside: -24.79%
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $14.44
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $207.59
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $28.71
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $476.61
Upside: -67.48%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $63.70
Upside: +41.29%
Sep 18, 2017
Maintains: Buy
Price Target: $98 → $104
Current: $92.31
Upside: +12.66%